AlphAIAlphAI — Financial news for AI agents
finanznachrichten.de$MRNA

Moderna, Inc.: Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates

Moderna reported Q3 2026 revenue of $1.3B, up 29% YoY, with GAAP net income of $0.2B and EPS of $0.38. The company raised its 2026 revenue growth outlook to 15%-25% and improved its operating expense and cash balance forecasts. It also announced FDA approval of mFLUSIVA and positive Phase 3 data for intismeran.

Original reporting
finanznachrichten.de
Published Nov 6, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MRNA
Bullish
high confidence
Mentioned
$MRNA
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to trigger a short-term rally, while the cash raise via convertible notes adds balance sheet strength.

02

Market read

First report of Moderna's earnings and guidance, providing fresh actionable data for traders.

03

What to watch

Potential headwinds from regulatory delays or competition in mRNA space are not reflected in the press release.

Relevance 8/10Novelty 9/10Timing: today

Background

Moderna's Q3 2026 earnings release includes updated revenue, profit, cash position, and guidance.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna reported Q3 2026 results with $1.3B revenue, $0.38 EPS and raised full-year revenue guidance to 15%-25%.

Expected impact

upward pressure as investors price in stronger revenue growth and cash balance

Evidence & confidence

Revenue beat, profit swing, and higher guidance are fresh material that typically drive buying.

Market effects

Sector

Biotech and vaccine manufacturers may see broader optimism from Moderna's strong results.

Regional

U.S. biotech sector could rally on the back of the earnings beat.

Global

Moderna's international vaccine sales boost confidence in global pharma demand.

Counterpoint

What could challenge this read

If guidance is overly optimistic, the stock could face a pullback on future earnings scrutiny.

Key entities

  • company
    Moderna, Inc.

    Biotech firm reporting Q3 2026 results.

Read at source← All news

StoryModerna posts Q3 profit, beats revenue estimates and lifts 2026 growth outlook

Also covered by

5 outlets

Related articles

$MRNAHighAI 9/10

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna (MRNA) reported Q3 2026 EPS of $0.38, beating estimates by $1.48. Revenue rose 29.2% YoY to $1.31B, driven by international COVID-19 vaccine sales. The company raised its 2026 sales outlook to 15-25% growth and reduced R&D spending plans. Shares rose in pre-market trading. Key products include mFlusiva and mCoflu vaccines, with mixed pipeline results.

zacks.com
$MRNAMedAI 8/10

WHO adds two more Ebola vaccines to clinical trial

WHO adds two Ebola vaccines, ChAdOx1 and mRNA-1469, to clinical trial in DRC. Developed by Oxford/Serum Institute and Moderna, they target the Bundibugyo virus. WHO's advisory group recommended further evaluation. Trial led by Institut National de Recherche Biomédicale and others. Current outbreak has caused over 4,600 cases and 2,100 deaths.

finance.yahoo.com
$MRNAMedAI 8/10

Moderna enjoys stable vaccine sales thanks to global COVID uptake

Moderna reported a 29% revenue increase to $1.3 billion for the quarter, driven by global COVID-19 vaccine sales. CFO Jamey Mock attributed growth to higher uptake of mNEXSPIKE and Spikevax. U.S. revenue is declining, but global expansion is leading sales. Moderna raised annual revenue expectations to 15-25%. Analysts noted strong vaccine sales and potential market share gains in the EU post-Pfizer's contract expiration.

biospace.com
$MRNAHighAI 8/10

What Moderna (MRNA) Said on Its Q3 Earnings Call

Moderna reported a 27% drop in R&D expenses to $583M in Q3, while SG&A expenses rose 5% to $282M. The company reduced its full-year R&D and capital expenditure estimates. Cash and investments increased to $8B. Moderna expects year-end cash of $8.1B-$8.3B. It announced progress in melanoma, renal cell carcinoma, and pancreatic cancer studies, and received FDA approval for its flu vaccine mFLUSIVA. The norovirus vaccine candidate did not meet interim success criteria.

finance.yahoo.com